Orphazyme A S(OZYMF)

Description: Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of orphan protein-misfolding diseases. It focuses on developing therapies for diseases caused by misfolding of proteins and lysosomal dysfunction. The company's lead candidate, Arimoclomol, is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. It also focuses on developing a series of heat-shock protein amplifying drugs. The company was founded in 2009 and is headquartered in Copenhagen, Denmark.

---

Keywords: Biopharmaceutical Organ Systems Rare Diseases Neurological Disorders Dysfunction Amyotrophic Lateral Sclerosis Copenhagen Orphan Disease Sclerosis Lomo Lipid Storage Disorders Type C Gaucher Disease Gaucher's Disease Niemann Arimoclomol Gaucher Inclusion Bodies Inclusion Body Myositis Niemann Pick Disease Niemann–Pick Disease

---

Home Page: www.orphazyme.com

Ole MaalOees Vej 3
Copenhagen, 2200
Denmark
Phone: 45 39 17 82 72

---

Officers

Exchange: PINK

Country: US

Currency: US Dollar ($)